A Phase 3 interventional study of Herpes Zoster vaccine GSK 1437173A and Boostrix in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 13 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-24.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 10th largest by enrollment, is one of 5 that started in 2014, is one of 22 in phase 3, and was the 12th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 5 started in 2014.
This study's enrollment of 935 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 11th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2014, is one of 25 in phase 3, and was the 22nd registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the Boostrix® vaccine in adults aged 50 years or older compared to administration of vaccines separately.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of non- may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
Exclusion Criteria:
Acute disease and/or fever at the time of enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received one injection of Boostrix vaccine and one injection of the GSK1437173A vaccine during the first visit and a second injection of the GSK1437173A vaccine during the third visit, two months later.
Biological: Herpes Zoster vaccine GSK 1437173A · Biological: Boostrix
Subjects received all vaccines separately i.e. one injection of Boostrix vaccine at the first visit, one injection of the GSK1437173A vaccine at the third visit and a second injection of the GSK1437173A vaccine at the fourth visit, all two months apart.
Biological: Herpes Zoster vaccine GSK 1437173A · Biological: Boostrix
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
Number of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in GSK1437173A Group
This outcome was required only for the GSK1437173A Group. Vaccine response defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.
Time frame: At 1 month post-Dose 2 (Month 3)
Antibody Concentrations Against Glycoprotein E (Anti-gE)
Antibody concentrations against glycoprotein E (gE) have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The reference seropositivity cut-off was an anti-gE antibody concentration greater than or equal to (≥) 97 mIU/mL.
Time frame: At 1 month post-Dose 2 (Month 3 for GSK1437173A Group adn Month 5 for Control Group)
Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) Antigens
Anti-PT, anti-FHA and anti-PRN antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).
Time frame: At 1 month post-Dose 1 (Month 1)
Antibody Concentrations Against Diphteria (Anti-D) and Tetanus (Anti-T) Antigens
Anti-PT, anti-FHA and anti-PRN antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).
Time frame: At 1 month post-Dose 1 (Month 1)
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Dose
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond (\>) 100 millimeters (mm). "0" Implied that no data was applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Study Vaccine
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond (\>) 100 millimeters (mm). "0" implies that: 1. No data were applicable for the GSK1437173A vaccine at Dose 1 for the Control Group, as it was only administered at Doses 2 and 3 in this group 2. No data were applicable for the Boostrix vaccine at Doses 2 and 3 for any of the groups, as it was only administered at Dose 1 for both the groups. 3. No data were applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Dose
Assessed solicited general symptoms were fatigue, gastrointestinal (symptoms included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as oral, axillary, rectal or tympanic temperature equal to or above (≥) 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = temperature above (\>) 39.0 °C. Related = general symptom assessed by the investigator as causally related to vaccination. "0" Implied that no data was applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Days With Solicited Symptoms
The number of days with local and general symptoms have been assessed during the solicited post-vaccination period. "0" Implied that no data was applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMDs assessed by the investigator as causally related to the study vaccination.
Time frame: From first vaccination up to study end (Day 0 to Month 14)
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: Within the 30-day (Days 0-29) post-vaccination period
Number of Subjects With Any Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From first vaccination up to study end (Day 0 to Month 14)
Not all subjects who were enrolled started the study due to elimination from statistical analyses or no vaccination received.
| Milestone | GSK1437173A Group | Control Group |
|---|---|---|
| Started | 412 | 418 |
| Completed | 396 | 398 |
| Not completed | 16 | 20 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Lost to follow-up | 8 | 11 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Enrolled in error | 1 | 0 |
| Withdrew: Lost due to crohn's disease | 0 | 1 |
| Milestone | GSK1437173A Group | Control Group |
|---|---|---|
| Started | 412 | 418 |
| Completed | 385 | 383 |
| Not completed | 27 | 35 |
| Withdrew: Adverse event | 6 | 3 |
| Withdrew: Lost to follow-up | 11 | 18 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Withdrawal by subject | 8 | 11 |
| Withdrew: Enrolled in error | 1 | 0 |
| Withdrew: Lost due to crohn's disease | 0 | 1 |
This outcome was required only for the GSK1437173A Group. Vaccine response defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.
| Participants | GSK1437173A Group |
|---|---|
| Number of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in GSK1437173A Group | 361 |
Antibody concentrations against glycoprotein E (gE) have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The reference seropositivity cut-off was an anti-gE antibody concentration greater than or equal to (≥) 97 mIU/mL.
| mIU/mL | GSK1437173A Group | Control Group |
|---|---|---|
| Antibody Concentrations Against Glycoprotein E (Anti-gE) | 51687.7 (48425.1 to 55170.1) | 57998.6 (54456.9 to 61770.6) |
Anti-PT, anti-FHA and anti-PRN antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).
| IU/mL | GSK1437173A Group | Control Group |
|---|---|---|
| Anti-PT | 41.1 (36.2 to 46.7) | 53.9 (47.4 to 61.4) |
| Anti-FHA | 309.3 (276.4 to 346.0) | 399.4 (359.1 to 444.3) |
| Anti-PRN | 222.6 (186.3 to 266.0) | 278.1 (232.9 to 332.0) |
Anti-PT, anti-FHA and anti-PRN antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).
| IU/mL | GSK1437173A Group | Control Group |
|---|---|---|
| Anti-D | 2.2 (1.9 to 2.6) | 2.5 (2.1 to 3.0) |
| Anti-T | 8.7 (7.8 to 9.7) | 10.1 (9.0 to 11.4) |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond (\>) 100 millimeters (mm). "0" Implied that no data was applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any Pain, Dose 1 | 315 | 156 |
| Grade 3 Pain, Dose 1 | 26 | 3 |
| Any Redness, Dose 1 | 119 | 18 |
| Grade 3 Redness, Dose 1 | 1 | 1 |
| Any Swelling, Dose 1 | 79 | 22 |
| Grade 3 Swelling, Dose 1 | 1 | 1 |
| Any Pain, Dose 2 | 289 | 299 |
| Grade 3 Pain, Dose 2 | 15 | 21 |
| Any Redness, Dose 2 | 116 | 102 |
| Grade 3 Redness, Dose 2 | 5 | 3 |
| Any Swelling, Dose 2 | 83 | 67 |
| Grade 3 Swelling, Dose 2 | 1 | 0 |
| Any Pain, Dose 3 | 0 | 282 |
| Grade 3 Pain, Dose 3 | 0 | 24 |
| Any Redness, Dose 3 | 0 | 101 |
| Grade 3 Redness, Dose 3 | 0 | 3 |
| Any Swelling, Dose 3 | 0 | 76 |
| Grade 3 Swelling, Dose 3 | 0 | 0 |
| Any Pain, Across doses | 346 | 357 |
| Grade 3 Pain, Across doses | 39 | 39 |
| Any Redness, Across doses | 167 | 148 |
| Grade 3 Redness, Across doses | 6 | 7 |
| Any Swelling, Across doses | 124 | 115 |
| Grade 3 Swelling, Across doses | 2 | 1 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond (\>) 100 millimeters (mm). "0" implies that: 1. No data were applicable for the GSK1437173A vaccine at Dose 1 for the Control Group, as it was only administered at Doses 2 and 3 in this group 2. No data were applicable for the Boostrix vaccine at Doses 2 and 3 for any of the groups, as it was only administered at Dose 1 for both the groups. 3. No data were applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any Pain, Boostrix vaccine, Dose 1 | 183 | 156 |
| Grade 3 Pain, Boostrix vaccine, Dose 1 | 8 | 3 |
| Any Pain, GSK1437173A vaccine, Dose 1 | 290 | 0 |
| Grade 3 Pain, GSK1437173A vaccine, Dose 1 | 20 | 0 |
| Any Redness, Boostrix vaccine, Dose 1 | 31 | 18 |
| Grade 3 Redness, Boostrix vaccine, Dose 1 | 0 | 1 |
| Any Redness, GSK1437173A vaccine, Dose 1 | 108 | 0 |
| Grade 3 Redness, GSK1437173A vaccine, Dose 1 | 1 | 0 |
| Any Swelling, Boostrix vaccine, Dose 1 | 23 | 22 |
| Grade 3 Swelling, Boostrix vaccine, Dose 1 | 0 | 1 |
| Any Swelling, GSK1437173A vaccine, Dose 1 | 67 | 0 |
| Grade 3 Swelling, GSK1437173A vaccine, Dose 1 | 1 | 0 |
| Any Pain, Boostrix vaccine, Dose 2 | 0 | 0 |
| Grade 3 Pain, Boostrix vaccine, Dose 2 | 0 | 0 |
| Any Pain, GSK1437173A vaccine, Dose 2 | 289 | 299 |
| Grade 3 Pain, GSK1437173A vaccine, Dose 2 | 15 | 21 |
| Any Redness, Boostrix vaccine, Dose 2 | 0 | 0 |
| Grade 3 Redness, Boostrix vaccine, Dose 2 | 0 | 0 |
| Any Redness, GSK1437173A vaccine, Dose 2 | 116 | 102 |
| Grade 3 Redness, GSK1437173A vaccine, Dose 2 | 5 | 3 |
| Any Swelling, Boostrix vaccine, Dose 2 | 0 | 0 |
| Grade 3 Swelling, Boostrix vaccine, Dose 2 | 0 | 0 |
| Any Swelling, GSK1437173A vaccine, Dose 2 | 83 | 67 |
| Grade 3 Swelling, GSK1437173A vaccine, Dose 2 | 1 | 0 |
| Any Pain, Boostrix vaccine, Dose 3 | 0 | 0 |
| Grade 3 Pain, Boostrix vaccine, Dose 3 | 0 | 0 |
| Any Pain, GSK1437173A vaccine, Dose 3 | 0 | 282 |
| Grade 3 Pain, GSK1437173A vaccine, Dose 3 | 0 | 24 |
| Any Redness, Boostrix vaccine, Dose 3 | 0 | 0 |
| Grade 3 Redness, Boostrix vaccine, Dose 3 | 0 | 0 |
| Any Redness, GSK1437173A vaccine, Dose 3 | 0 | 101 |
| Grade 3 Redness, GSK1437173A vaccine, Dose 3 | 0 | 3 |
| Any Swelling, Boostrix vaccine, Dose 3 | 0 | 0 |
| Grade 3 Swelling, Boostrix vaccine, Dose 3 | 0 | 0 |
| Any Swelling, GSK1437173A vaccine, Dose 3 | 0 | 76 |
| Grade 3 Swelling, GSK1437173A vaccine, Dose 3 | 0 | 0 |
| Any Pain, Boostrix vaccine, Across doses | 183 | 156 |
| Grade 3 Pain, Boostrix vaccine, Across doses | 8 | 3 |
| Any Pain, GSK1437173A vaccine, Across doses | 339 | 344 |
| Grade 3 Pain, GSK1437173A vaccine, Across doses | 34 | 37 |
| Any Redness, Boostrix vaccine, Across doses | 31 | 18 |
| Grade 3 Redness, Boostrix vaccine, Across doses | 0 | 1 |
| Any Redness, GSK1437173A vaccine, Across doses | 163 | 144 |
| Grade 3 Redness, GSK1437173A vaccine, Across doses | 6 | 6 |
| Any Swelling, Boostrix vaccine, Across doses | 23 | 22 |
| Grade 3 Swelling, Boostrix vaccine, Across doses | 0 | 1 |
| Any Swelling, GSK1437173A vaccine, Across doses | 117 | 109 |
| Grade 3 Swelling, GSK1437173A vaccine,Across doses | 2 | 0 |
Assessed solicited general symptoms were fatigue, gastrointestinal (symptoms included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as oral, axillary, rectal or tympanic temperature equal to or above (≥) 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = temperature above (\>) 39.0 °C. Related = general symptom assessed by the investigator as causally related to vaccination. "0" Implied that no data was applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any Fatigue, Dose 1 | 129 | 65 |
| Grade 3 Fatigue, Dose 1 | 12 | 7 |
| Related Fatigue, Dose 1 | 88 | 37 |
| Any Gastrointestinal, Dose 1 | 52 | 35 |
| Grade 3 Gastrointestinal, Dose 1 | 2 | 3 |
| Related Gastrointestinal, Dose 1 | 25 | 16 |
| Any Headache, Dose 1 | 106 | 60 |
| Grade 3 Headache, Dose 1 | 7 | 3 |
| Related Headache, Dose 1 | 74 | 32 |
| Any Myalgia, Dose 1 | 177 | 102 |
| Grade 3 Myalgia, Dose 1 | 12 | 4 |
| Related Myalgia, Dose 1 | 134 | 76 |
| Any Shivering, Dose 1 | 64 | 16 |
| Grade 3 Shivering, Dose 1 | 6 | 3 |
| Related Shivering, Dose 1 | 48 | 8 |
| Any Temperature, Dose 1 | 36 | 7 |
| Grade 3 Temperature, Dose 1 | 2 | 0 |
| Related Temperature, Dose 1 | 26 | 5 |
| Any Fatigue, Dose 2 | 137 | 110 |
| Grade 3 Fatigue, Dose 2 | 22 | 9 |
| Related Fatigue, Dose 2 | 101 | 74 |
| Any Gastrointestinal, Dose 2 | 51 | 46 |
| Grade 3 Gastrointestinal, Dose 2 | 5 | 5 |
| Related Gastrointestinal, Dose 2 | 34 | 28 |
| Any Headache, Dose 2 | 99 | 82 |
| Grade 3 Headache, Dose 2 | 10 | 8 |
| Related Headache, Dose 2 | 74 | 54 |
| Any Myalgia, Dose 2 | 160 | 155 |
| Grade 3 Myalgia, Dose 2 | 17 | 16 |
| Related Myalgia, Dose 2 | 122 | 116 |
| Any Shivering, Dose 2 | 79 | 38 |
| Grade 3 Shivering, Dose 2 | 12 | 4 |
| Related Shivering, Dose 2 | 60 | 27 |
| Any Temperature, Dose 2 | 51 | 23 |
| Grade 3 Temperature, Dose 2 | 2 | 0 |
| Related Temperature, Dose 2 | 32 | 16 |
| Any Fatigue, Dose 3 | 0 | 130 |
| Grade 3 Fatigue, Dose 3 | 0 | 14 |
| Related Fatigue, Dose 3 | 0 | 92 |
| Any Gastrointestinal, Dose 3 | 0 | 54 |
| Grade 3 Gastrointestinal, Dose 3 | 0 | 3 |
| Related Gastrointestinal, Dose 3 | 0 | 37 |
| Any Headache, Dose 3 | 0 | 95 |
| Grade 3 Headache, Dose 3 | 0 | 8 |
| Related Headache, Dose 3 | 0 | 69 |
| Any Myalgia, Dose 3 | 0 | 164 |
| Grade 3 Myalgia, Dose 3 | 0 | 19 |
| Related Myalgia, Dose 3 | 0 | 124 |
| Any Shivering, Dose 3 | 0 | 65 |
| Grade 3 Shivering, Dose 3 | 0 | 11 |
| Related Shivering, Dose 3 | 0 | 50 |
| Any Temperature, Dose 3 | 0 | 43 |
| Grade 3 Temperature, Dose 3 | 0 | 1 |
| Related Temperature, Dose 3 | 0 | 28 |
| Any Fatigue, Across doses | 186 | 192 |
| Grade 3 Fatigue, Across doses | 30 | 27 |
| Related Fatigue, Across doses | 143 | 134 |
| Any Gastrointestinal, Across doses | 85 | 97 |
| Grade 3 Gastrointestinal, Across doses | 7 | 9 |
| Related Gastrointestinal, Across doses | 51 | 62 |
| Any Headache, Across doses | 152 | 158 |
| Grade 3 Headache, Across doses | 16 | 15 |
| Related Headache, Across doses | 118 | 108 |
| Any Myalgia, Across doses | 227 | 243 |
| Grade 3 Myalgia, Across doses | 27 | 32 |
| Related Myalgia, Across doses | 176 | 186 |
| Any Shivering, Across doses | 112 | 100 |
| Grade 3 Shivering, Across doses | 18 | 16 |
| Related Shivering, Across doses | 86 | 72 |
| Any Temperature, Across doses | 72 | 63 |
| Grade 3 Temperature, Across doses | 3 | 1 |
| Related Temperature, Across doses | 48 | 41 |
The number of days with local and general symptoms have been assessed during the solicited post-vaccination period. "0" Implied that no data was applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses
| Days | GSK1437173A Group | Control Group |
|---|---|---|
| Pain, Dose 1 | 3.2 (2.0 to 4.0) | 2.6 (2.0 to 3.0) |
| Pain, Dose 2 | 2.8 (2.0 to 4.0) | 2.9 (2.0 to 4.0) |
| Pain, Dose 3 | — | 2.7 (2.0 to 3.0) |
| Redness, Dose 1 | 3.3 (2.0 to 5.0) | 3.0 (2.0 to 5.0) |
| Redness, Dose 2 | 3.2 (2.0 to 4.0) | 3.2 (2.0 to 4.0) |
| Redness, Dose 3 | — | 2.9 (2.0 to 4.0) |
| Swelling, Dose 1 | 3.3 (2.0 to 5.0) | 3.5 (2.0 to 5.0) |
| Swelling, Dose 2 | 3.1 (2.0 to 4.0) | 3.0 (2.0 to 4.0) |
| Swelling, Dose 3 | — | 2.9 (2.0 to 4.0) |
| Fatigue, Dose 1 | 2.4 (1.0 to 3.0) | 2.5 (1.0 to 4.0) |
| Fatigue, Dose 2 | 2.3 (1.0 to 3.0) | 2.7 (1.0 to 3.0) |
| Fatigue, Dose 3 | — | 2.6 (1.0 to 4.0) |
| Gastrointestinal, Dose 1 | 2.3 (1.0 to 4.0) | 2.1 (1.0 to 3.0) |
| Gastrointestinal, Dose 2 | 2.0 (1.0 to 2.0) | 2.3 (1.0 to 3.0) |
| Gastrointestinal, Dose 3 | — | 1.9 (1.0 to 3.0) |
| Headache, Dose 1 | 1.8 (1.0 to 2.0) | 2.2 (1.0 to 2.0) |
| Headache, Dose 2 | 1.9 (1.0 to 2.0) | 2.1 (1.0 to 3.0) |
| Headache, Dose 3 | — | 2.0 (1.0 to 2.0) |
| Myalgia, Dose 1 | 2.9 (2.0 to 4.0) | 2.3 (1.0 to 3.0) |
| Myalgia, Dose 2 | 2.7 (2.0 to 3.5) | 2.9 (1.0 to 4.0) |
| Myalgia, Dose 3 | — | 2.7 (1.0 to 3.0) |
| Shivering, Dose 1 | 1.6 (1.0 to 2.0) | 2.3 (1.0 to 3.0) |
| Shivering, Dose 2 | 1.6 (1.0 to 2.0) | 1.6 (1.0 to 2.0) |
| Shivering, Dose 3 | — | 1.5 (1.0 to 1.0) |
| Temperature, Dose 1 | 1.7 (1.0 to 2.0) | 2.4 (1.0 to 3.0) |
| Temperature, Dose 2 | 1.6 (1.0 to 2.0) | 1.5 (1.0 to 1.0) |
| Temperature, Dose 3 | — | 1.5 (1.0 to 2.0) |
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMDs assessed by the investigator as causally related to the study vaccination.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any pIMD(s) | 0 | 0 |
| Related pIMD(s) | 0 | 0 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any AE(s) | 105 | 118 |
| Grade 3 AE(s) | 10 | 15 |
| Related AE(s) | 27 | 31 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Number of Subjects With Any Serious Adverse Events (SAEs) | 21 | 31 |
Collected over Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: within the 30-day (Days 0-29) post-vaccination period; SAEs: from first vaccination up to study end at Month 14.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A Group | 4/412 (1%) | 21/412 (5.1%) | 368/412 (89.3%) |
| Control Group | 5/418 (1.2%) | 31/418 (7.4%) | 380/418 (90.9%) |
| Event | GSK1437173A Group | Control Group |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 4/412 | 1/418 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/412 | 3/418 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/412 | 2/418 |
| PneumoniaInfections and infestations | 1/412 | 2/418 |
| AnaemiaBlood and lymphatic system disorders | 1/412 | 0/418 |
| Acute myocardial infarctionCardiac disorders | 1/412 | 1/418 |
| Cardiac arrestCardiac disorders | 1/412 | 0/418 |
| Chest painGeneral disorders | 1/412 | 0/418 |
| CholelithiasisHepatobiliary disorders | 1/412 | 0/418 |
| Bacterial sepsisInfections and infestations | 1/412 | 0/418 |
| Event | GSK1437173A Group | Control Group |
|---|---|---|
| PainGeneral disorders | 346/412 | 357/418 |
| MyalgiaMusculoskeletal and connective tissue disorders | 228/412 | 243/418 |
| FatigueGeneral disorders | 186/412 | 192/418 |
| ErythemaSkin and subcutaneous tissue disorders | 167/412 | 148/418 |
| HeadacheNervous system disorders | 153/412 | 159/418 |
| SwellingGeneral disorders | 124/412 | 115/418 |
| ChillsGeneral disorders | 112/412 | 102/418 |
| Gastrointestinal disorderGastrointestinal disorders | 85/412 | 97/418 |
| PyrexiaGeneral disorders | 74/412 | 64/418 |
| Age, Continuous(Years) | GSK1437173A Group | Control Group | Total |
|---|---|---|---|
| Mean | 63.4 ± 8.4 | 63.1 ± 9.0 | 63.25 ± 8.7 |
| Sex: Female, Male(Participants) | GSK1437173A Group | Control Group | Total |
|---|---|---|---|
| Female | 222 | 225 | 447 |
| Male | 190 | 193 | 383 |
| Race/Ethnicity, Customized(Participants) | GSK1437173A Group | Control Group | Total |
|---|---|---|---|
| Geographic ancestry — African Heritage/African American | 41 | 53 | 94 |
| Geographic ancestry — American Indian or Alaskan Native | 1 | 1 | 2 |
| Geographic ancestry — Asian - Central/South Asian Heritage | 0 | 1 | 1 |
| Geographic ancestry — Asian - East Asian Heritage | 0 | 1 | 1 |
| Geographic ancestry — Asian - Japanese Heritage | 1 | 0 | 1 |
| Geographic ancestry — White - Arabic/North African Heritage | 3 | 0 | 3 |
| Geographic ancestry — White - Caucasian/European Heritage | 364 | 357 | 721 |
| Geographic ancestry — Mixed Origin | 2 | 5 | 7 |
Ran from Feb 2014 to primary completion in Jun 2015, 16 months.
Results were first posted in Apr 2018, 2 years 10 months after primary completion. A results delay was requested in Jun 2016.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 16 months is close to that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Shingrix · Boostrix